Skip to contents
Ana Carrizossa Anderson, PhD
Associate Scientist, Brigham and Women's Hospital
Associate Professor of Neurology, Harvard Medical School

Brigham and Women's Hospital
Department of Neurology
75 Francis Street
Boston, MA 02115

Research Location: Harvard Institute of Medicine


Edit Profile


Research Narrative:

Dr. Anderson is an Assistant Professor of Neurology at Harvard Medical School and Associate Scientist at the Brigham and Women’s Hospital, Boston. She obtained her B.S. in Microbiology and Immunology in 1993 from the University of Miami, where she graduated summa cum laude. She obtained her Ph.D. in Immunology from Harvard University in 1999.  During her Ph.D. she was awarded a fellowship from the Howard Hughes Medical Institute.

Dr. Anderson works in the field of cancer immunology, specifically on the role of inhibitory molecules in regulation of the anti-tumor T cell response. Her laboratory identified the inhibitory molecule Tim-3 as a key regulator of T cell dysfunction in cancer. Prior to working in the field of cancer immunology, Dr. Anderson worked in the field of autoimmunity. Dr. Anderson has published over 35 original papers, 11 reviews, and 5 book chapters. Her work on T cell cross-reactivity in auotimmunity was selected by Nature Immunology as a ‘Classic Paper in Autoimmunity’. She has also had several papers selected as either ‘must-read’ or ‘recommended’ by the Faculty of 1000. Dr. Anderson is an associate member of the Faculty of 1000 and is on the editorial board for OncoImmunology. Dr. Anderson currently serves on the scientific advisory board for CoStim Pharmaceuticals.


Education:
Harvard University, 1999, PhD
PhD

Publications (Pulled from Harvard Catalyst Profiles):

1. Singer M, Anderson AC. Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies. Cancer Immunol Res. 2019 Feb; 7(2):168-173.

2. Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen O, Kuchroo VK, Regev A, Anderson AC. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. Immunity. 2019 01 15; 50(1):181-194.e6.

3. Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, Nyman J, Marjanovic ND, Kowalczyk MS, Wang C, Kurtulus S, Law T, Etminan Y, Nevin J, Buckley CD, Burkett PR, Buenrostro JD, Rozenblatt-Rosen O, Anderson AC, Regev A, Kuchroo VK. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018 06; 558(7710):454-459.

4. Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin Cancer Res. 2018 Jun 01; 24(11):2574-2584.

5. Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, Kurtulus S, Kassam N, Sobel RA, Fukumura D, Jain RK, Anderson AC, Kuchroo VK, Joller N. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. J Immunol. 2018 04 15; 200(8):3000-3007.

6. Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, Xia J, Kwon JYH, Nevin J, Herbst RH, Yanai I, Rozenblatt-Rosen O, Kuchroo VK, Regev A, Anderson AC. A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell. 2017 11 16; 171(5):1221-1223.

7. Sabatos-Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F, Taraszka J, Wesemann L, Pertel T, Acharya N, Klapholz M, Etminan Y, Jiang X, Huang YH, Blumberg RS, Kuchroo VK, Anderson AC. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. Oncoimmunology. 2018; 7(2):e1385690.

8. Wang C, Singer M, Anderson AC. Molecular Dissection of CD8+ T-Cell Dysfunction. Trends Immunol. 2017 08; 38(8):567-576.

9. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017 03; 276(1):112-120.

10. Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, Xia J, Kwon JYH, Nevin J, Herbst RH, Yanai I, Rozenblatt-Rosen O, Kuchroo VK, Regev A, Anderson AC. A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell. 2016 Sep 08; 166(6):1500-1511.e9.